Developing therapies for Cardiovascular and Cardiometabolic disease
Dr. Jonathan Ward, CEO
Genome Biologics is a resident company of Johnson & Johnson Innovation - JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.
Genome Biologics is a leader company in therapeutic target and drug discovery in cardiovascular and cardiometabolic disease. Its technology platforms seamlessly integrate synergistically to accelerate development of therapies to treat illnesses where no other treatments have proven effective or ever existed.
They have a rich therapy pipeline in Cardiotoxicity, Heart failure and Hypertrophic cardiomyopathy. Strategies employed in these therapies include cellular metabolic modulation and the reactivation of cardiac regeneration. “We are at the forefront of translating Ai-driven big data analysis into precision preclinical organoid (TrueCardium™) and in vivo disease models for therapeutic validation”, company affirms. This synergistic workflow expedites drug discovery and development.
Genome Biologics mission is to identify novel cardiac therapies through targeting of the disease transcriptome. Founded in 2016, the company won the EIC SME Instrument Phase 1 and the German Biotechnology Day challenge award in 2017, becoming founder resident at Johnson & Johnson Innovation - JLABS in Beerse, Belgium. In 2018, they won the EIC SME Instrument Phase 2 and Merck Venture Lounge award. Its Ai-driven GENIMAPS and preclinical GENISYST precision disease modelling technology has led to joint and in-house drug development programs with MedChem and Pharma. In addition to funding and support from the European Union Innovation Council (EIC), JLABS, Medical Research Council (MRC/UKRI), Hessen Trade and Invest and Goethe University Frankfurt, Genome Biologics has raised private investment for indication specific programs.
